TriplHelix, Inc.

Class 044: Medical services, namely treating medical patients through biologic and genomic therapies in the fields of reversing biological aging and treating cancer through telomeric attrition, epigenetic and regenerative therapeutics; Medical services, namely treating medical patients with biologic and genomic therapies that restore tissue function, enhance immune competence, and promote cell regeneration based on proprietary secretome formulations, encapsulated gene therapies, and cell-based delivery platforms; Medical services, namely treating medical patients with thymic based cell regeneration therapies, secretome-driven rejuvenation therapies, gene therapies, cryoblation and immunotherapy for medical purposes; None of the foregoing for use in the research and data analytics for population health, geneaology, virology, or epidemiology.

Gene therapy research; Research in the field of gene editing technology; Laboratory research in the field of gene expression; Development of pharmaceuticals for cell and gene therapies; Laboratory research services in the field of gene expression; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Research and development services in the field of gene expression systems; Providing laboratory research services in the field of gene expression, namely, cancer biology